Benefits
Entecavir 0.5mg is used in the treatment of chronic hepatitis B virus (HBV) infection in adults and children aged 2 years and older with evidence of active viral replication and liver inflammation.
How It Works
Entecavir is an antiviral medicine that belongs to the class of nucleoside analogs. It works by inhibiting the replication of the hepatitis B virus, reducing its ability to multiply and infect new liver cells, thereby helping to decrease liver inflammation and slow down the progression of the disease.
Side Effects
Headache, Fatigue, Dizziness, Nausea,Vomiting, Diarrhea, Stomach pain, Trouble sleeping (insomnia).
Expert's Advice
- Take Entecavir on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).
- Complete the full course as prescribed by your doctor, even if symptoms improve.
- Regular blood tests may be required to monitor your liver function and viral load during treatment.
- Do not stop taking Entecavir without consulting your doctor, as this may lead to worsening of the infection.
- Avoid alcohol, as it may increase the risk of liver damage.
- Inform your doctor if you have any kidney issues, as dosage adjustments may be needed.
- Women should avoid breastfeeding while taking Entecavir.
Frequently Asked Questions
Q. How long does it take for Entecavir to start working?
The effectiveness of Entecavir may take several weeks to months, as it works to reduce viral load and liver inflammation. Regular monitoring will help assess progress.
Q. Can Entecavir cure hepatitis B?
Entecavir helps to manage chronic hepatitis B by lowering viral load and liver damage, but it is not a cure. Long-term therapy may be needed to control the infection.
Q. What happens if I miss a dose of Entecavir?
If you miss a dose, take it as soon as you remember, unless it is almost time for the next dose. Do not take two doses at once to make up for the missed dose.
Q. Can I take Entecavir if I have HIV?
Entecavir is not effective for HIV infection. It is essential to test for HIV before starting Entecavir, as it may impact HIV treatment in co-infected patients.